Antihypertensive prescribing preferences in three South Indian Hospitals: Cost analysis, physicians perspectives and emerging trends

International Journal of Clinical Pharmacology and Therapeutics

Volumn 49, Issue 4, 2011, Pages 277-285

  Sreedharan, N ^a   Rao, P G M ^a   Rau, N R ^b   Shankar, P R ^c  

^a MANIPAL COLLEGE OF PHARMACEUTICAL SCIENCES   (India)

^b KASTURBA MEDICAL COLLEGE   (India)

^c KIST MEDICAL COLLEGE   (Nepal)

Author keywords

Hypertension; Physician perspectives; Prescription analysis; South India

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; THIAZIDE DIURETIC AGENT;

ADULT; AGED; ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; COST BENEFIT ANALYSIS; CROSS-SECTIONAL STUDY; DRUG DOSE REGIMEN; DRUG PREFERENCE; ESSENTIAL HYPERTENSION; FEMALE; HUMAN; INDIA; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PHYSICIAN ATTITUDE; PRESCRIPTION; PROSPECTIVE STUDY; TREND STUDY;

ADULT; AGED; ANTIHYPERTENSIVE AGENTS; CALCIUM CHANNEL BLOCKERS; COSTS AND COST ANALYSIS; DRUG THERAPY, COMBINATION; DRUG UTILIZATION; FEMALE; HUMANS; INDIA; MALE; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS;

EID: 79955962750     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CP201464     Document Type: Article

References (22)

1. Callow AD. Cardiovascular disease 2005 - the global picture. Vascul Pharmacol. 2006; 45: 302-307.
2. Ghaffar A, Reddy KS, Singhi M. Burden of noncommunicable diseases in South Asia. Br Med J. 2004; 328: 807-810. (Pubitemid 38446379)
3. Joshi SR, Parikh RM. India - diabetes capital of the world: now heading towards hypertension. J Assoc Physicians India. 2007; 55: 323-324.
4. Sowers JR, Epstein M, Frohlich ED. Diabetes, hypertension, and cardiovascular disease: an update. Hypertension. 2001; 37: 1053-1059.
5. Hathial M. Blood pressure control among Indians with hypertension: the I-Target survey. J Indian Med Assoc. 2007; 105: 401-402, 404, 410.
6. Central Drugs Standard Control Organization. Directorate General of Health Services,Ministry of Health and Family Welfare, Government of India, http://cdsco.nic.in/listofdrugapprovedmain.html.
7. Weber MA, Materson BJ. Hypertension guidelines: a major reappraisal critically examines the available evidence. J Clin Hypertens (Greenwich). 2010; 12: 229-236.
8. Bimo, Chaudary A, Das A, Diwan V, Kafle KK, Mabadeje B, et al. How to investigate drug use in health facilities (selected drug use indicator) action programme on essential drugs. WHO official publication. 1995.
9. Current Index of Medical Specialities.
10. Frank J. Managing hypertension using combination therapy. Am Fam Physician. 2008; 77: 1279-1286.
11. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, Jr., Jones DW, Materson BJ, Oparil S,Wright JT, Jr., Roccella EJ. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003; 289: 2560-2572. (Pubitemid 37430158)
12. ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). Jama. 2000; 283: 1967-1975.
13. Brown MJ, Palmer CR, Castaigne A, de Leeuw PW, Mancia G, Rosenthal T, Ruilope LM. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calciumchannel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet. 2000; 356: 366-372. (Pubitemid 30487492)
14. MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results. Br Med J. 1992; 304: 405-412.
15. Davis BR, Piller LB, Cutler JA, Furberg C, Dunn K, Franklin S, Goff D, Leenen F, Mohiuddin S, Papademetriou V, Proschan M, Ellsworth A, Golden J, Colon P, Crow R. Role of diuretics in the prevention of heart failure: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Circulation. 2006; 113: 2201-2210.
16. Dahlof B, Sever PS, Poulter NR,Wedel H, Beevers DG, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005; 366: 895-906. (Pubitemid 41265663)
17. Messerli FH, Bangalore S, Julius S. Risk/benefit assessment of beta-blockers and diuretics precludes their use for first-line therapy in hypertension. Circulation. 2008; 117: 2706-2715; discussion 2715.
18. National Collaborating Centre for Chronic Conditions. Hypertension: Management of Hypertension in Adults in Primary Care: Partial Update. London, UK: Royal College of Physicians; 2006.
19. Lindgren P, Buxton M, Kahan T, Poulter NR, Dahlof B, Sever PS, Wedel H, Jonsson B. Economic evaluation of ASCOT-BPLA: antihypertensive treatmentwith an amlodipine-based regimen is cost effective compared with an atenolol-based regimen. Heart. 2008; 94: 4.
20. Kaplan NM, Opie LH. Controversies in hypertension. Lancet. 2006; 367: 168-176. (Pubitemid 43077131)
21. Jhaj R, Goel NK, Gautam CS, Hota D, Sangeeta B, Sood A, Sachdev A. Prescribing patterns and cost of antihypertensive drugs in an internal medicine clinic. Indian Heart J: 2001; 53: 323-327. (Pubitemid 33607898)
22. Tiwari H, Kumar A, SK K. Prescription monitoring of anti-hypertensive drug utilisation at the Panjab University Health Centre in India. Sing Med J. 2004; 45: 117-120. (Pubitemid 38987107)